Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.59) by 44.07 percent. This is a 85.27 percent increase over losses of $(2.24) per share from the same period last year. The company reported quarterly sales of $18.692 million which beat the analyst consensus estimate of $12.720 million by 46.95 percent. This is a 131.22 percent increase over sales of $8.084 million the same period last year.